Literature DB >> 23030640

Inclusion of compliance and persistence in economic models: past, present and future.

Ananth Kadambi1, Robert J Leipold, Anuraag R Kansal, Sonja Sorensen, Denis Getsios.   

Abstract

Economic models are developed to provide decision makers with information related to the real-world effectiveness of therapeutics, screening and diagnostic regimens. Although compliance with these regimens often has a significant impact on real-world clinical outcomes and costs, compliance and persistence have historically been addressed in a relatively superficial fashion in economic models. In this review, we present a discussion of the current state of economic modelling as it relates to the consideration of compliance and persistence. We discuss the challenges associated with the inclusion of compliance and persistence in economic models and provide an in-depth review of recent modelling literature that considers compliance or persistence, including a brief summary of previous reviews on this topic and a survey of published models from 2005 to 2012. We review the recent literature in detail, providing a therapeutic-area-specific discussion of the approaches and conclusions drawn from the inclusion of compliance or persistence in economic models. In virtually all publications, variation of model parameters related to compliance and persistence was shown to have a significant impact on predictions of economic outcomes. Growing recognition of the importance of compliance and persistence in the context of economic evaluations has led to an increasing number of economic models that consider these factors, as well as the use of more sophisticated modelling techniques such as individual simulations that provide an avenue for more rigorous consideration of compliance and persistence than is possible with more traditional methods. However, we note areas of continuing concern cited by previous reviews, including inconsistent definitions, documentation and tenuous assumptions required to estimate the effect of compliance and persistence. Finally, we discuss potential means to surmount these challenges via more focused efforts to collect compliance and persistence data.

Mesh:

Year:  2012        PMID: 23030640     DOI: 10.1007/bf03261872

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  4 in total

Review 1.  Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.

Authors:  Dyfrig Hughes; Joanna Charles; Dalia Dawoud; Rhiannon Tudor Edwards; Emily Holmes; Carys Jones; Paul Parham; Catrin Plumpton; Colin Ridyard; Huw Lloyd-Williams; Eifiona Wood; Seow Tien Yeo
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

2.  Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.

Authors:  Simon Frey; Roland Linder; Georg Juckel; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2013-02-19

3.  Economic evaluation of Cardio inCode®, a clinical-genetic function for coronary heart disease risk assessment.

Authors:  A Ramírez de Arellano; A Coca; M de la Figuera; C Rubio-Terrés; D Rubio-Rodríguez; A Gracia; A Boldeanu; J Puig-Gilberte; E Salas
Journal:  Appl Health Econ Health Policy       Date:  2013-10       Impact factor: 2.561

4.  Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Methodological Papers.

Authors:  Abualbishr Alshreef; Nicholas Latimer; Paul Tappenden; Ruth Wong; Dyfrig Hughes; James Fotheringham; Simon Dixon
Journal:  Med Decis Making       Date:  2019-10-24       Impact factor: 2.583

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.